There is exactly one peptide in this category with an FDA approval behind it, and the approval is more specific than the marketing. Bremelanotide — prescribed as Vyleesi, sold far more widely as research-grade PT-141 — is approved for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Its label carries an explicit Limitation of Use: not indicated for HSDD in postmenopausal women.
That sentence is the story of this page. At 44 and still cycling, you are closer to the studied population than the internet realises. At 53 and a year past your last period, you are outside it by the label's own words. And the peptides marketed for midlife mood? Studied in Russian psychiatric patients with diagnosed anxiety disorders, and in stroke rehabilitation wards.
The short version
What this page concludes
Bremelanotide / PT-141 Mixed — real approval, randomised data in 1,267 women, a modest effect, and a safety profile skipped in every affiliate post. Premenopausal women only.
Selank Thin — two small Russian trials in diagnosed anxiety disorders, against a benzodiazepine unavailable in the West.
Semax Thin — studied in ischaemic stroke rehabilitation. Not mood, not healthy midlife women.
Transdermal testosterone for postmenopausal HSDD Supported — 36 randomised trials, 8,480 participants, an international consensus statement. Not a peptide, and the strongest evidence here.
Vaginal oestrogen and vaginal DHEA for GSM Supported — the symptom cluster nobody writing about peptides mentions, and often the real cause of what gets called low libido.
What actually changes, and when
The Study of Women's Health Across the Nation followed 3,302 women aged 42 to 52 through six annual visits. Adjusting for age, health, psychological function and social circumstances, two outcomes moved with menopausal stage: desire fell by late perimenopause, and vaginal or pelvic pain during intercourse rose. Arousal, orgasm, emotional satisfaction with a partner and how important sex felt were not independently associated with stage at all.
Pain rose; desire fell; everything else tracked health, mood and relationship. Which means "my libido has gone" is often two problems wearing one label — and one of them has good treatments that have nothing to do with peptides.
Distress is the other half. In a national survey of 31,581 US women, 43.1% reported some sexual problem, but only 12.0% reported a problem plus personal distress — the combination that defines a clinical condition. That peaked at 14.8% in women aged 45 to 64. Low desire without distress is not a disorder. Low desire with distress, in roughly one in seven midlife women, is.
Mood follows its own curve: in SWAN, the transition carried a higher risk of major depression than premenopause, with prior depression the strongest predictor. A window of vulnerability, not a guarantee.
PT-141: what the approval actually says
Bremelanotide is a melanocortin receptor agonist, injected under the skin at least 45 minutes before anticipated sexual activity. It is used episodically, not daily. FDA approved June 2019.
From the Vyleesi label
"VYLEESI is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)."
Limitations of Use: "Not indicated for treatment of HSDD in postmenopausal women or in men." Also not indicated to improve sexual performance.
"Acquired" means a change from a previous baseline, not lifelong. "Generalized" means not confined to one partner or situation. The trials did not enrol women who had always had low desire, or whose desire was situational.
The population question nobody handles correctly
The two Phase 3 trials randomised 1,267 women. Mean age 39. Age range 19 to 56. That range clearly overlaps the years when many women are perimenopausal — but participants were classified as premenopausal, and the trials were designed, analysed and labelled that way. The population was narrow in other respects too: 85.6% white, 96.6% from US sites.
So the honest statement is three-part, and almost nobody makes it:
- It is approved in premenopausal women.
- It has never been studied in a population characterised as perimenopausal.
- It is explicitly not indicated once you are postmenopausal.
Off-label use therefore gets less supported the further through the transition you are. Not "it stops working on the day of your final period" — nobody knows that. But the evidence thins, and no trial tells you where on that slope you sit. Sites writing "FDA approved for women" have flattened a real distinction into a marketing line.
How big was the effect
Improvement over placebo in the Female Sexual Function Index desire domain in Studies 301 and 302. Both P<.001 — statistically real. Both small in absolute terms on a scale running 1.2 to 6.0.
Distress related to low desire also improved: −0.37 in Study 301 (P<.001) and −0.29 in Study 302 (P=.005). Genuine, replicated, placebo-controlled — and modest. Any page reporting the P value without the effect size is telling you half the result. There is no efficacy data beyond 24 weeks, and the label directs clinicians to discontinue after 8 weeks without improvement.
The safety profile marketing skips
of women on bremelanotide discontinued because of adverse reactions, versus 2% on placebo. Nine times the placebo rate, for a drug taken by choice, before sex.
Nausea occurred in 40% of patients. 13% required anti-emetics; 8% stopped for nausea alone. It was worst with the first dose and improved for most women afterwards — but a two-in-five nausea rate is a real tolerability problem, not a footnote.
Contraindicated in uncontrolled hypertension or known cardiovascular disease
Not a soft warning — a contraindication on the label. Bremelanotide produces transient rises of up to 6 mmHg systolic and 3 mmHg diastolic, with heart rate falling up to 5 beats per minute, peaking 2 to 4 hours post-dose and generally resolving within 12 hours.
Why this matters more here than in the trial: blood pressure rises with age, and the menopause transition itself carries adverse cardiovascular risk changes — the American Heart Association issued a scientific statement on exactly that. A 39-year-old trial cohort is not a 51-year-old reader. If your blood pressure has not been measured recently, that comes first.
The dosing cap is the safety profile
Focal hyperpigmentation — darkened patches on the face, gums or breasts — was higher in patients with darker skin, and does not always resolve on stopping.
Hyperpigmentation at the labelled maximum of 8 doses per month, versus a separate study dosing daily for 8 days. The monthly cap is not bureaucratic caution. It is the finding.
Which is the practical point for anyone buying research-grade PT-141 rather than prescribed Vyleesi: you get the molecule without the label that tells you how often not to use it.
Two interactions matter. Naltrexone: bremelanotide may significantly decrease systemic exposure of oral naltrexone, and the label says avoid — relevant given how widely low-dose naltrexone is prescribed in midlife women's health. Oral drugs generally: it may slow gastric emptying and affect absorption of oral hormone therapy, thyroid medication, or anything with a narrow therapeutic window.
Mood: where there very much isn't
Selank and Semax are genuinely approved pharmaceuticals — in Russia. Neither has FDA status. ClinicalTrials.gov lists zero Semax studies; the two hits for "Selank" are false text matches, not trials.
Selank Thin
Two published clinical studies underpin the entire category, both from the same Moscow research network: n=60, comparing selank against phenazepam in patients with phobic-anxiety and somatoform disorders (ICD-10 F40.2–9, F41.1–9, F45.0–1); and n=70, comparing phenazepam alone (30 patients) against phenazepam plus selank (40 patients) in anxiety-phobic, hypochondriacal and somatoform disorders.
Read what that is. The participants were psychiatric patients with diagnosed anxiety disorders. The comparator was phenazepam, a benzodiazepine not available in the West. The second study's headline finding is that selank reduced the benzodiazepine's side effects and let its effect arrive faster — a finding about benzodiazepine co-therapy, not about a woman with no diagnosis who wants to feel less on edge at 3pm. Both papers are in Russian-language journals, often without placebo or blinding, never replicated outside Russia.
Semax Thin
Semax is sold for focus, mood and brain fog. The trials are in ischaemic stroke rehabilitation. The best-known enrolled 110 patients after stroke, dosing 6,000 mcg/day in two ten-day courses, and measured plasma BDNF, motor performance and the Barthel index.
Credit where it is genuinely due
That trial enrolled 43 men and 67 women, mean age 58 — women in the majority. In a field where ipamorelin's only human pharmacology study used eight healthy men per dose level and tesamorelin's pivotal trials were 85% male, that is rare enough to name. It is still stroke rehabilitation. A Barthel index improvement after a stroke says nothing about mood in a healthy 49-year-old.
Side by side
| Compound | Claimed for | Approval status | Population actually studied | Effect size | Key safety limit |
|---|---|---|---|---|---|
| Bremelanotide (Vyleesi, prescription) | Low sexual desire | FDA approved 2019 — premenopausal HSDD only; not indicated postmenopause | 1,267 women, mean age 39, range 19–56, classified premenopausal; 85.6% white, 96.6% US | FSFI-desire +0.30 and +0.42 vs placebo, P<.001 — modest | Contraindicated in uncontrolled hypertension or CV disease. Max 8 doses/month |
| PT-141 (research-grade vial) | The same, off-label | None. Same molecule, no label, no pharmacist, no dose counter | Same trials — but no data at unlabelled doses, and ~30% of tested vials have been mislabelled, misdosed or contaminated | Unknown at unlabelled doses | As above, plus 38% hyperpigmentation with daily dosing |
| Selank | Anxiety, mood support | No FDA status. Russian approval. Zero registered trials | n=60 and n=70 psychiatric patients with ICD-10 anxiety disorders, vs/with phenazepam | Reported anxiolytic effect; no placebo-controlled replication | Unknown outside that population. No perimenopausal data |
| Semax | Focus, mood, brain fog | No FDA status. Russian approval. Zero registered trials | n=110 stroke rehabilitation patients (43 men, 67 women, mean age 58) | BDNF rise, faster Barthel recovery — in stroke patients | Never studied for mood in people without stroke |
What actually has evidence for midlife desire
Here is the part most peptide sites will not write, because it does not sell a vial. Low desire in midlife is real, common and under-treated — and it has options with far better evidence than anything above.
Testosterone Supported
A systematic review and meta-analysis of 36 randomised controlled trials, 8,480 participants, found that in postmenopausal women testosterone significantly increased satisfying sexual event frequency (mean difference 0.85 events), desire (SMD 0.36), arousal, orgasm, pleasure and self-image, and reduced sexual distress. No serious adverse events; acne and hair growth were more common. Oral testosterone worsened the lipid profile, non-oral routes did not — which is why every guideline says transdermal.
The 2019 Global Consensus Position Statement — endorsed by the International Menopause Society, the Endocrine Society, ACOG, NAMS and ISSWSH among others — concluded that the only evidence-based indication for testosterone in women is HSDD in postmenopausal women, after formal biopsychosocial assessment. Its other conclusions are routinely overstated:
- No demonstrated effect on general wellbeing or depressed mood. Testosterone is not a mood treatment.
- No demonstrated effect on cognition, bone mineral density, lean mass, body fat or muscle strength at 12 months.
- Insufficient data to recommend it in premenopausal women, for anything.
- Pellets and injections, which produce supraphysiological levels, are not recommended; nor is compounded "bioidentical" testosterone where an approved equivalent exists.
- Blood testosterone should not be used to diagnose. Measure at baseline, at 3–6 weeks, then six-monthly, and stop if there is no benefit by six months.
The catch, stated plainly
There is no FDA-approved testosterone product for women in the United States. Prescribing means a fraction of an approved male product off-label, dosed to keep levels in the physiological female range. The consensus statement calls that reasonable where no female product exists — meaning you need a clinician who measures levels, not a clinic that sells pellets.
Note the mirror image: testosterone's evidence is postmenopausal; bremelanotide's is premenopausal. Perimenopause sits in the gap. That is the honest reason this is hard, and the reason nobody should be selling you certainty about it.
Genitourinary syndrome of menopause
Every one of the six pages currently ranking for peptides and perimenopausal libido skips this entirely — and for a large share of women it is the actual answer. Genitourinary syndrome of menopause (GSM) is the current term for what falling oestrogen does to vulvar, vaginal and lower urinary tract tissue: dryness, burning, loss of lubrication, pain during sex, urinary urgency and frequency, discomfort on urinating, and recurrent urinary tract infections.
of postmenopausal women are affected by GSM, per the 2020 position statement of The North American Menopause Society — which also concluded it is likely underdiagnosed and undertreated.
Two consequences matter here. GSM is progressive: unlike hot flushes, which usually subside, genitourinary symptoms tend to persist and worsen untreated. And if sex hurts, desire falls — not psychology, learning; SWAN found pain rising through the transition alongside desire falling. A drug acting on melanocortin receptors in the brain does not lubricate tissue or reverse atrophy. If pain is the driver, a desire drug is aimed at the wrong end, and you will conclude it "didn't work" for reasons unrelated to the drug.
What has evidence for GSM
A 2024 systematic review in Annals of Internal Medicine, funded by AHRQ and PCORI, assessed 46 randomised trials. Its findings, with its certainty ratings:
| Option | For | Evidence | What it shows | Caveat |
|---|---|---|---|---|
| Vaginal oestrogen (cream, tablet, ring) | Dryness, painful sex, urinary symptoms | 22 RCTs in the AHRQ review; Cochrane review of 30 RCTs, 6,235 women Supported | May improve dryness, dyspareunia, most bothersome symptom and satisfaction vs placebo | Low certainty; most trials ≤12 weeks. Endometrial safety not studied beyond 1 year |
| Vaginal DHEA (prasterone) | Dryness, painful sex | Among 16 non-oestrogen hormone RCTs Supported | May improve dryness, dyspareunia and genitourinary bother | Low certainty; long-term endometrial data lacking |
| Oral ospemifene | Painful sex, dryness | Randomised data in the same review Supported | May improve dryness, dyspareunia and satisfaction | Oral and systemic, with its own warnings. Low certainty |
| Vaginal moisturisers and lubricants | Dryness; friction at the time of sex | 4 RCTs; recommended in NAMS guidance Mixed | May improve dryness; enough for many with mild symptoms | Do not change the tissue |
| Vaginal testosterone, systemic DHEA, vaginal oxytocin, oral raloxifene | Marketed for GSM | Reviewed in the same 46 trials Thin | May provide no benefit (low certainty), or uncertain effects | Being hormonal and vaginal is not the same as working |
| Energy-based devices (vaginal laser) | GSM | NAMS 2020 Thin | Insufficient placebo-controlled trials to judge efficacy or safety | Expensive, marketed hard, and the guideline declines to recommend it |
| PT-141 / bremelanotide | Desire | Not studied for GSM No human data | Acts centrally on desire. Does nothing to vulvovaginal tissue | Nobody has tested it here, because that is not what it does |
The order of operations most women are never given
If sex is painful, or you have dryness, urgency or recurrent UTIs, treat that first and give it eight to twelve weeks — the cheapest, best-evidenced, most reversible intervention here. Then see what is left of the desire problem. Much of what gets called low libido at 49 is pain, the anticipation of pain, or a bladder dictating the day.
Vaginal oestrogen at GSM doses produces very low systemic absorption, which is why NAMS states a progestogen is not indicated alongside it. With a history of breast cancer this is a decision for you and your oncologist — NAMS says there are insufficient data to confirm safety in that group, which is a call for a conversation, not an automatic no.
If you're going to buy, buy from someone who tests
ZestyRat publishes batch COAs and third-party purity results. Given that independent testing has found problems in roughly 30% of peptide vials on the market, this is the part that matters most.
Mood: what the evidence supports
If low mood and anxiety arrived alongside the rest of the transition, the interventions with real randomised data are not peptides.
Transdermal oestradiol. In a 12-month randomised, double-blind, placebo-controlled trial of 172 initially non-depressed perimenopausal and early postmenopausal women aged 45–60, transdermal oestradiol plus intermittent micronised progesterone reduced the odds of clinically significant depressive symptoms: 17.3% scored 16 or above on the CES-D at least once, versus 32.3% on placebo (OR 2.5). The benefit was concentrated in the early menopause transition and absent later. An earlier crossover study found oestradiol improved mood in perimenopause-related depression. A real, stage-dependent effect — and a prescription decision. If you are weighing hormone therapy alongside peptides, read peptides and HRT first: oral oestrogen opposes the entire growth-hormone peptide category in a way no clinic protocol discloses.
Cognitive behavioural therapy. The 2023 non-hormone therapy position statement of The North American Menopause Society recommends CBT for menopause symptoms. In the MENOS 2 randomised trial, group and self-help CBT both reduced the problem rating of hot flushes and night sweats, with improvements in mood and quality of life. No side effects, no vial, no purity question.
Sleep. The layer most often missed. Night sweats fragment sleep, fragmented sleep degrades mood and desire, and both get attributed to hormones alone. Treating the disruption underneath often improves more than one symptom at once — see sleep in perimenopause, and energy and brain fog for the Semax and GH-secretagogue cognitive claims in full.
Where to stop reading and call someone
If your mood has changed in a way that is persistent, is affecting your ability to work or care for people, or includes thoughts of harming yourself, that is a medical situation with effective treatments and not a peptide question. See a clinician. Depression during the menopause transition is well described and treatable.
How to think about this
1. Is it pain, or is it desire? If penetration hurts, if you are dry, if you have urinary symptoms — that is GSM, and it has the best evidence base on this page. Desire cannot be assessed clearly until it is addressed.
2. Where are you in the transition? Still cycling, even irregularly, puts you nearer the population where bremelanotide was studied. A year or more past your final period puts you in the group the label excludes — and the group where testosterone has the evidence instead. This one fact should change the conversation, and almost never does.
3. Is distress present? Low desire without distress is a variant, not a disorder. HSDD requires that the change bothers you — that is what the trials enrolled on, and it separates a symptom to treat from a life stage to accommodate.
If you proceed anyway, the label limits nobody is handing you are the ones to hold yourself to: the monthly dose cap, the blood pressure contraindication, the eight-week stop rule. And since independent testing has found problems in roughly 30% of peptide vials, what is in the vial matters more than the protocol. Related: weight in perimenopause, skin, hair and collagen, muscle and bone.
Is PT-141 FDA approved for women?
Partly, and the qualifier is the answer. Bremelanotide (Vyleesi) is approved for acquired, generalised hypoactive sexual desire disorder in premenopausal women, with an explicit Limitation of Use: not indicated for HSDD in postmenopausal women or in men. "FDA approved for women" is true only of premenopausal women with a specific diagnosis.
Does PT-141 work in perimenopause?
Nobody has tested it in women characterised as perimenopausal. The Phase 3 trials enrolled 1,267 women, mean age 39, range 19 to 56 — the range overlaps perimenopause substantially, but participants were classified as premenopausal and the drug is labelled that way. Support thins the further through the transition you are, and stops at the label's boundary once you are postmenopausal.
How big was the effect in the trials?
Modest. The Female Sexual Function Index desire domain improved by 0.30 over placebo in Study 301 and 0.42 in Study 302, both at P<.001. Distress also fell. Real, replicated, small in absolute terms. No efficacy data beyond 24 weeks, and the label directs discontinuation at 8 weeks without improvement.
What are the main side effects of bremelanotide?
Nausea in 40% of patients, with 13% needing anti-emetics and 8% stopping for nausea alone. Overall 18% discontinued for adverse reactions versus 2% on placebo. It causes transient rises of up to 6 mmHg systolic and a heart rate fall of up to 5 bpm, peaking 2 to 4 hours post-dose, and is contraindicated in uncontrolled hypertension or known cardiovascular disease. Focal hyperpigmentation occurred in about 1% at up to 8 doses per month, but 38% dosed daily for 8 days.
Do Selank or Semax help with perimenopausal mood or anxiety?
Nobody has tested either in perimenopausal women. Selank was studied in two small Russian trials, n=60 and n=70, in patients with diagnosed ICD-10 anxiety disorders, against or added to phenazepam — a benzodiazepine not available in the West. Semax trials are in ischaemic stroke rehabilitation. Neither has FDA status, and neither has been replicated outside Russia.
Is testosterone better evidence than PT-141 for perimenopausal libido?
Stronger evidence, for a different group. A meta-analysis of 36 randomised trials in 8,480 participants found testosterone improved desire, arousal, orgasm, pleasure and satisfying sexual event frequency, and reduced distress, in postmenopausal women. The 2019 Global Consensus Position Statement calls postmenopausal HSDD the only evidence-based indication. Bremelanotide's evidence is premenopausal. Perimenopause sits in the gap.
Can peptides help with vaginal dryness or painful sex?
No peptide has been tested for genitourinary syndrome of menopause. What has randomised evidence is vaginal oestrogen, vaginal DHEA (prasterone), oral ospemifene and, for milder symptoms, vaginal moisturisers. A 2024 systematic review of 46 randomised trials found each may improve dryness and painful sex at low certainty, while vaginal testosterone, systemic DHEA, vaginal oxytocin and oral raloxifene or bazedoxifene may provide no benefit. Treat this first: pain during sex reliably reduces desire.
Sources
- Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol 2019;134(5):899-908. PMID 31599840.
- US Food and Drug Administration. VYLEESI (bremelanotide) injection, for subcutaneous use — full prescribing information. NDA 210557, 2019.
- Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the use of Testosterone Therapy for Women. Maturitas 2019;128:89-93. PMID 31484631.
- Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol 2019;7(10):754-766. PMID 31353194.
- The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause 2020;27(9):976-992. PMID 32852449.
- Danan ER, Sowerby C, Ullman KE, et al. Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause: A Systematic Review. Ann Intern Med 2024;177(10):1400-1414. PMID 39250810.
- Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2016;8:CD001500. PMID 27577677.
- Palacios S, Nappi RE, Bruyniks N, Particco M, Panay N; EVES Study Investigators. The European Vulvovaginal Epidemiological Survey (EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause. Climacteric 2018;21(3):286-291. PMID 29553288.
- Avis NE, Brockwell S, Randolph JF Jr, et al. Longitudinal changes in sexual functioning as women transition through menopause: results from the Study of Women's Health Across the Nation. Menopause 2009;16(3):442-452. PMID 19212271.
- Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 2008;112(5):970-978. PMID 18978095.
- Gordon JL, Rubinow DR, Eisenlohr-Moul TA, et al. Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial. JAMA Psychiatry 2018;75(2):149-157. PMID 29322164.
- Schmidt PJ, Nieman L, Danaceau MA, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol 2000;183(2):414-420. PMID 10942479.
- Bromberger JT, Kravitz HM, Chang YF, et al. Major depression during and after the menopausal transition: Study of Women's Health Across the Nation (SWAN). Psychol Med 2011;41(9):1879-1888. PMID 21306662.
- The North American Menopause Society. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause 2023;30(6):573-590. PMID 37252752.
- Ayers B, Smith M, Hellier J, Mann E, Hunter MS. Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial. Menopause 2012;19(7):749-759. PMID 22336748.
- El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation 2020;142(25):e506-e532. PMID 33251828.
- Medvedev VE, Tereshchenko ON, Israelian AIu, et al. A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova 2014;114(7):17-22 [in Russian]. PMID 25176261.
- Medvedev VE, Tereshchenko ON, Kost NV, et al. Optimization of the treatment of anxiety disorders with selank. Zh Nevrol Psikhiatr Im S S Korsakova 2015;115(6):33-40 [in Russian]. PMID 26356395.
- Gusev EI, Martynov MY, Kostenko EV, Petrova LV, Bobyreva SN. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova 2018;118(3 Pt 2):61-68 [in Russian]. PMID 29798983.
- Leung KC, Johannsson G, Leong GM, Ho KK. Estrogen regulation of growth hormone action. Endocr Rev 2004;25(5):693-721. PMID 15466938.